Data May Provide “Framework” for Mitigating Cancer Surgery Disparities

Commentary
Video

Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.

Data from a retrospective analysis indicated how residential segregation may contribute to inequalities in cancer mortality for patients who undergo surgery, which may provide a “framework” for future policies designed to mitigate these disparities, said Muhammad Talha Waheed, MD.

Waheed, a research fellow in the Department of Surgical Oncology at City of Hope National Medical Center in Duarte, California, spoke with CancerNetwork® about findings presented at the 2024 Society of Surgical Oncology Annual Meeting (SSO) from a study assessing the impact of racial/economic segregation on patient-level accessibility, timeliness, and appropriateness of treatment for cancer.

Although Waheed stated that the presentation highlighted inequities in access to care and mortality across different demographics, he acknowledged that exploring the mechanisms that drive these disparities is another question that must be addressed. Additionally, he said that he would share the results of his study with policymakers in California to help inspire legislature that may improve treatment access and quality for patients in disadvantaged areas.

Transcript:

This study highlights the issues that are on the systemic level and brings forward the impact of very longstanding racist policies. It’ll be hard to do anything each year to address these issues. The study shows the zip codes, areas, and disease sites that are being affected the most, and it sheds [light] on the mechanism that is driving these disparate survivals. That was the biggest question. It’s easier to find this disparate access and mortality, but what are the mechanisms that are driving these differences?

These are important points that we need to focus on. It provides the framework for state- and federal-level policies to prioritize and target these areas, the disease sites, accessibility, and timeliness appropriateness of cancer treatment. These patients residing in disadvantaged areas should have equal access and quality of cancer care. We will share these findings with stakeholders and policymakers in California. They can maybe use this as a guiding principle and make some policies.

Reference

Waheed MT, Sullivan KM, Haye S, et al. Impact of racialized residential segregation on guideline concordant cancer care and survival. Presented at the Society of Surgical Oncology (SSO) 2024 Annual Meeting; March 20 – 23, 2024; Atlanta, GA; abstract E126.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Related Content